Antibiotic resistance has become a major global health crisis in recent years. The overuse and misuse of antibiotics has led many bacteria to develop resistance, rendering some of our most important antibiotics ineffective. This has created an urgent need to explore alternative treatment options. One such promising alternative receiving renewed interest is bacteriophage therapy.
What is Bacteriophage Therapy?
Bacteriophage therapy, also known as phage therapy, is the use of bacteriophages (viruses that infect bacteria) to treat bacterial infections. Bacteriophages or phages are the most abundant life form on Earth, with an estimated 1031 phage particles in the biosphere.
Phages are highly host-specific, meaning an individual phage species can generally only infect one or a few species of bacteria. When a phage infects a bacterium, it hijacks the bacterium’s DNA replication machinery and uses it to produce multiple copies of itself. The resulting copies then burst out of the bacterial cell, killing it. Typically, new phage particles then go on to seek out and infect other similar bacteria.
In phage therapy, purified phages that can infect and kill specific pathogenic bacterial strains are administered to patients. The phages then infect and destroy the targeted bacteria, resolving the infection. Phages are very host-specific, so they do not affect the native microbiota of the patient.
Coherent Market Insights explores in Bacteriophage Therapy Market how with the alarming rise of superbugs resistant to all known antibiotics, phage therapy is gaining traction as a safe and effective method to treat otherwise untreatable infections.
History and Resurgence of Phage Therapy
The discovery of phages is credited to British bacteriologist Frederick Twort in 1915 and French-Canadian microbiologist Félix d’Herelle in 1917. D’Herelle was the first to propose using phages to treat infections, coining the term “bacteriophage” and pioneering early phage therapy research in the 1920s. However, with the widespread discovery and use of antibiotics in the mid-20th century, research and clinical application of phage therapy diminished in the Western world.
In the former Soviet Union and Eastern European countries, phage therapy continued to be actively researched and clinically applied. Over the past few decades, the re-emergence of multi-drug resistant bacterial infections has renewed global interest in phage therapy. Several clinical trials have demonstrated phage therapy’s safety and efficacy against bacterial infections resistant to antibiotics. The promising results have led the Food and Drug Administration (FDA) and European Medicines Agency (EMA) to become more receptive toward developing phage therapy as an alternative.
Advantages of Phage Therapy
Some key potential advantages of phage therapy over conventional antibiotics include:
– Host-specificity: Phages only target the infecting pathogen, avoiding disruption to the normal microbiota. This prevents side effects like diarrhea associated with broad-spectrum antibiotics.
– Self-replication: Phages multiply at the site of infection, with increased bacterial killing as the infection progresses. In contrast, antibiotics are consumed and excreted from the body over time.
– Polyvalency: Cocktails of phages with differing host ranges can be used against multiple strains of a pathogen, reducing development of resistance.
– Resistant mutation prevention: Simultaneous infection by multiple phages makes it more difficult for resistance to develop compared to a single antibiotic.
– Fewer side effects: Phages are not absorbed systemically and face less issues like allergic reactions compared to many antibiotics.
– Natural alternatives: Phages are natural bacterial predators present ubiquitously in the environment, avoiding concerns of pharmalogical drugs.
Emerging Clinical Applications
Several Phase I-III clinical trials have demonstrated phage therapy’s safety and efficacy in treating various infections like:
– E. coli causing gastrointestinal infections
– Staphylococcus aureus causing skin infections
– Pseudomonas aeruginosa infections in cystic fibrosis patients
– Multi-drug resistant Acinetobacterbaumannii wounds and sepsis
– Methicillin-resistant Staphylococcus aureus (MRSA)
In addition to the above, researchers are also exploring using phages against other pathogens like Salmonella, Klebsiella, and Mycobacterium tuberculosis. Phages are also being researched as an alternative to treat antibiotic-resistant infections like Clostridium difficile colitis.
Phage cocktails developed specifically against multi-drug resistant bacterial strains hold promise, especially in case of hospital-acquired infections. Topical phage application also shows potential in chronic wound infections. Phage endolysins (phage-encoded enzymes) are being developed as an alternative to traditional antibiotics.
Commercialization Challenges
While promising, significant challenges remain for fully commercializing phage therapy globally. The regulatory frameworks for phage therapy development are still evolving. Clinical trials must demonstrate safety, efficacy and batch-to-batch consistency to gain approvals. Issues regarding intellectual property, product development and shelf life also need to be addressed.
High costs of development and bureaucratic hurdles have deterred phage therapy commercialization compared to conventional drugs. Limited market-size and inconsistent demand also reduce commercial viability compared to antibiotics. However, as antibiotic resistance increases globally, interest in sustainable phage therapy is growing steadily among both researchers and regulatory authorities.
Market Outlook
As discussed in the recent market research report published by Coherent Market Insights, the global bacteriophage market is projected to witness significant growth over the forecast period. Significant research funding and a more receptive regulatory environment are driving the market. Continued discovery of multidrug-resistant bacterial strains is increasing the demand for alternative treatment options.
While Europe and North America currently dominate the bacteriophage market, Asia Pacific region is expected to emerge as the fastest growing market. Increasing investments in bacteriophage research by countries like India, China, and South Korea are contributing to this growth. The demand for phage-based products and therapeutics is also expected to rise as global healthcare systems seek more sustainable solutions to combat antibiotic resistance. However, further large-scale clinical trials are still needed to demonstrate real-world effectiveness and validate the commercial potential.
